14-day Premium Trial Subscription Try For FreeTry Free
Viking Therapeutics (VKTX) and Zealand Pharma report a successful phase 2 for weight loss drugs. Maurits Pot discusses the emergence of strong weight loss drug players.
Press Release – No. 2 / 2024 Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results Copenhagen, Denmark, February 20, 2024 – a Zealand Pha
Zealand Pharma A/S (ZEAL) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Anna Krassowska - Vice President-Investor Relations Adam Steensberg - President & Chief Exec
Press Release – No. 9 / 2023 Zealand Pharma Hosts Conference Call on August 17 at 2pm CET (8am ET) to Present First Half 2023 Results Copenhagen, Denmark, August 14, 2023 – a Zealand Pharma A/
Press Release– No. 3 / 2023 Zealand Pharma Hosts Conference Call on May 11 at 2pm CET (8am ET) to Present First Quarter 2023 Results Copenhagen, Denmark, May 4, 2023 – a Zealand Pharma A/S (CVR
Zealand Pharma A/S (ZEAL) Q4 2022 Results Conference Call March 1, 2022 8:00 AM ET Company Participants Anna Krassowska - VP, IR Adam Steensberg - President, CEO Henriette Wennicke - CFO David Kendall
Zealand Pharma A/S (ZEAL) Q3 2022 Earnings Conference Call November 10, 2022 10:00 AM ET Company Participants Anna Krassowska - Vice President, Investor Relations & Corporate Communications Adam Steen
Zealand Pharma A/S (ZEAL) Q2 2022 Earnings Conference Call August 11, 2022 10:00 AM ET Company Participants Anna Krassowska - VP of IR and Corporate Communications Adam Steensberg - President and CEO
Zealand Pharma AS (ZEAL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength do
Press release – No. 3 / 202 2

Why Zealand Pharma Shares Are Rising

10:41am, Thursday, 19'th May 2022
Zealand Pharma A/S - ADR (NASDAQ: ZEAL) shares are trading higher by 17.01% at $13.69 after the company announced the results from its phase 3 trial of Dasiglucagon in pediatric patients with congenit
Zealand Pharma A/S (NASDAQ: ZEAL) has announced topline results from its second Phase 3 trial of dasiglucagon in pediatric patients with congenital hyperinsulinism (CHI), a condition in which indiv
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE